Disparities in prostate cancer epidemiology: a comparative analysis of West Africa and Europe

Aleece Warner; Francis Chinegwundoh

doi:10.51496/jogm.v5.279

Authors

Aleece Warner Department of Urology, Barts Health NHS Trust, Newham University Hospital, London, United Kingdom
Francis Chinegwundoh Department of Urology, Barts Health NHS Trust, Newham University Hospital, London, United Kingdom

DOI:

https://doi.org/10.51496/jogm.v5.279

Keywords:

prostate cancer, West Africa, European countries, Prostate cancer incidence, screening methods

Abstract

Prostate cancer remains a leading cause of morbidity and mortality worldwide, disproportionately affecting black men. This review examines the differences in prostate cancer incidence and mortality rates between West Africa and Europe. While prostate cancer is more prevalent in Europe, primarily attributed to widespread screening programmes, West Africa faces significant challenges, including underdeveloped cancer registration systems, low public awareness, and limited access to screening. These factors lead to underreporting of incidence rates, yet higher mortality rates. In addition, this narrative review explores the role of environmental and lifestyle factors, including high levels of chronic stress and exposure to pollutants, as additional risk factors for prostate cancer in West Africa compared to European countries. As the global incidence of prostate cancer is projected to increase, implementing region-specific interventions and targeting modifiable lifestyle factors will be vital in alleviating the burden in West Africa. Addressing these disparities is essential for improving early detection, enhancing survival outcomes, and promoting more equitable prostate cancer care.

Metrics

Metrics Loading ...

References

Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer. JAMA 2017; 317(24): 2532. doi: 10.1001/jama.2017.7248 DOI: https://doi.org/10.1001/jama.2017.7248

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74(3): 229–63. doi: 10.3322/caac.21834 DOI: https://doi.org/10.3322/caac.21834

Zhang W, Cao G, Wu F, Wang Y, Liu Z, Hao Hu et al. Global burden of prostate cancer and association with socioeconomic status, 1990–2019: A systematic analysis from the global burden of disease study. J Epidemiol Glob Health 2023; 13(3): 407–21. doi: 10.1007/s44197-023-00103-6 DOI: https://doi.org/10.1007/s44197-023-00103-6

Kearney G, Chen M, Mula-Hussain L, Skelton M, Eren M, Orio PF, et al. Burden of prostate cancer in the Middle East: a comparative analysis based on global cancer observatory data. Cancer Med 2023; 12(23): 21419–25. doi: 10.1002/cam4.6689 DOI: https://doi.org/10.1002/cam4.6689

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of Black race with prostate cancer–specific and other-cause mortality. JAMA Oncol 2019; 5(7): 975. doi: 10.1001/jamaoncol.2019.0826 DOI: https://doi.org/10.1001/jamaoncol.2019.0826

Chinegwundoh F, Enver M, Lee A, Nargund V, Oliver T , Ben-Shlomo Y, et al. Risk and presenting features of prostate cancer amongst African-Caribbean, South Asian and European men in north-east London. BJU Int 2006; 98(6): 1216–20. doi: 10.1111/j.1464-410x.2006.06503.x DOI: https://doi.org/10.1111/j.1464-410X.2006.06503.x

James ND, Tannock I, N’Dow J, Feng F, Gillessen S, Ali SA, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 2024; 403(10437): 1683–722. doi: 10.1016/s0140-6736(24)00651-2 DOI: https://doi.org/10.1016/S0140-6736(24)00651-2

Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. IARC Scientific Publication No. 951991. Lyon: International Agency for Research on Cancer; 1991.

Omotoso O, Teibo JO, Atiba FA, Oladimeji T, Paimo OK, Ataya FS, et al. Addressing cancer care inequities in sub-Saharan Africa: current challenges and proposed solutions. Int J Equity Health 2023; 22(1): 189. doi: 10.1186/s12939-023-01962-y DOI: https://doi.org/10.1186/s12939-023-01962-y

Jedy-Agba EE, Oga EA, Odutola M, Abdullahi YM, Popoola A, Achara P, et al. Developing national cancer registration in developing countries – case study of the Nigerian national system of cancer registries. Front Public Health 2015; 3: 186. doi: 10.3389/fpubh.2015.00186 DOI: https://doi.org/10.3389/fpubh.2015.00186

Global Cancer Observatory (GCO). Globocan 2022: new global cancer data. International Agency for Research on Cancer (IARC); 2022. Available from: https://gco.iarc.fr [cited 10 February 2025].

Giusti F, Martos C, Trama A, Bettio M, Sanvisens A, Audisio R, Arndt V, et al. Cancer treatment data available in European cancer registries: where are we and where are we going? Front Oncol 2023; 13: 1109978. doi: 10.3389/fonc.2023.1109978 DOI: https://doi.org/10.3389/fonc.2023.1109978

Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 2016; 14(1): 26–7. doi: 10.1038/nrurol.2016.251 DOI: https://doi.org/10.1038/nrurol.2016.251

Vaccarella S, Li M, Bray F, Serraino D, Lorenzoni V, Auvinen A, et al. Prostate cancer incidence and mortality in Europe and implications for screening activities: population based study. BMJ 2024; 386: e077738. doi: 10.1136/bmj-2023-077738 DOI: https://doi.org/10.1136/bmj-2023-077738

Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reames RR, et al. Prostate cancer disparities in black men of African descent: a comparative literature review of prostate cancer burden among black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agents Cancer 2009; 4(Suppl. 1): S2. doi: 10.1186/1750-9378-4-s1-s2 DOI: https://doi.org/10.1186/1750-9378-4-S1-S2

World Health Organization. Early diagnosis of cancer: a guide for health professionals. Available from: https://www.who.int/cancer/early-diagnosis [cited 3 February 2025].

Seraphin TP, Joko-Fru WY, Hammer L, Griesel M, NCS Mezger, Feuchtner JC, et al. Presentation, patterns of care, and outcomes of patients with prostate cancer in sub-Saharan Africa: a population-based registry study. Cancer 2021; 127(22): 4221–32. doi: 10.1002/cncr.33818 DOI: https://doi.org/10.1002/cncr.33818

Adedeji IA, Lawal SA, Aluko-Arowolo S. Prostate cancer knowledge gaps among community stakeholders in rural Nigeria: implications for seeking screening. Cancer Causes Control 2021; 32(8): 895–901. doi: 10.1007/s10552-021-01444-y DOI: https://doi.org/10.1007/s10552-021-01444-y

Rivera Colón O, Bolajoko O, Odedina F. Comparison of health access, lifestyle, prostate cancer knowledge and screening among black men residing in West Africa and the USA. EcancerMedicalScience 2021; 15: 1309. doi: 10.3332/ecancer.2021.1309 DOI: https://doi.org/10.3332/ecancer.2021.1309

Bamidele O, et al. A scoping review of stigma related to prostate cancer in Black Men. J Racial Ethn Health Disparities 2024. doi: 10.1007/s40615-024-02070-5 DOI: https://doi.org/10.1007/s40615-024-02070-5

Thompson IM. Overdiagnosis and overtreatment of prostate cancer. Am Soc Clin Oncol Educ Book 2012; 32(1): e35–9. doi: 10.14694/edbook_am.2012.32.98 DOI: https://doi.org/10.14694/EdBook_AM.2012.32.98

Matsukawa A, Yanagisawa T, Bekku K, Parizi MK, Laukhtina E, Klemm J, et al. Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 2024; 7(4): 697–704. doi: 10.1016/j.euo.2023.12.005 DOI: https://doi.org/10.1016/j.euo.2023.12.005

Fazekas T, Shim SR, Basile G, Baboudijan M, Kói T, Przydacz M, et al. Magnetic resonance imaging in prostate cancer screening. JAMA Oncol 2024; 10(6): 745. doi: 10.1001/jamaoncol.2024.0734 DOI: https://doi.org/10.1001/jamaoncol.2024.0734

Tolani MA, Agbo CA, Paciorek A, Umar SS, Ojewola RW, Mohmmed F, et al. Detection and management of localized prostate cancer in Nigeria: barriers and facilitators according to patients, caregivers and healthcare providers. BMC Health Serv Res 2024; 24(1): 918. doi: 10.1186/s12913-024-11340-1 DOI: https://doi.org/10.1186/s12913-024-11340-1

Ugochukwu UV, Odukoya OO, Ajogwu A, Ojewola RW, et al. Prostate cancer screening: what do men know, think and do about their risk? Exploring the opinions of men in an urban area in Lagos State, Nigeria: a mixed methods survey. Pan Afr Med J 2019; 34: 168. doi: 10.11604/pamj.2019.34.168.20921 DOI: https://doi.org/10.11604/pamj.2019.34.168.20921

de Vos II, Meertens A, Hogenhout R, Remmers S, Roobol MJ, et al. A detailed evaluation of the effect of prostate-specific antigen–based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam section of the European randomised study of screening for prostate cancer. Eur Urol 2023; 84(4): 426–34. doi: 10.1016/j.eururo.2023.03.016 DOI: https://doi.org/10.1016/j.eururo.2023.03.016

Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ, et al. A European model for an organised risk-stratified early detection programme for prostate cancer. Eur Urol Oncol 2021; 4(5): 731–9. doi: 10.1016/j.euo.2021.06.006 DOI: https://doi.org/10.1016/j.euo.2021.06.006

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. Guidelines for the prostate cancer. European Association of Urology; 2024. Available from: https://uroweb.org/guidelines/prostate-cancer [cited 1 March 2025].

International Agency for Research on Cancer. Estimated number of deaths from 2020 to 2040, males [0–85+], prostate, Africa. Cancer Tomorrow. World Health Organization; 2021. Available from: https://www.iarc.fr [cited 15 February 2025].

European Association of Urology. EAU guidelines. Arnhem, The Netherlands: European Association of Urology; 2024. Presented at: 39th Annual EAU Congress; 5–8 April 2024; Paris, France.

Iheanacho CO, Enechukwu OH. Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review. Cancer Causes Control 2024; 36(1): 1–12. doi: 10.1007/s10552-024-01917-w DOI: https://doi.org/10.1007/s10552-024-01917-w

Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer 2017; 24(12): T297–310. doi: 10.1530/erc-17-0145 DOI: https://doi.org/10.1530/ERC-17-0145

Cassell A, Yunusa B, Jalloh M, Ndoye M, Mbodji MM, Diallo A, et al. Management of advanced and metastatic prostate cancer: a need for a sub-Saharan guideline. J Oncol 2019; 2019: 1–9. doi: 10.1155/2019/1785428 DOI: https://doi.org/10.1155/2019/1785428

Udoh EA, Akaiso OE, Ukpong AE, Essiet IU. Cost-effectiveness of bilateral orchidectomy in the treatment of advanced prostate cancer. World J Biomed Res 2022; 9(1): 17–22.

Shokaier, G., Gross, M., Cohen, M., & Hussein, A. Mental health after orchiectomy: systematic review and strategic management. Arab J Urol 2025; 1–8. doi: 10.1080/20905998.2025.2478771 DOI: https://doi.org/10.1080/20905998.2025.2478771

Weiner AB, Cohen JE, DeLancey JO, Schaeffer EM, Auffenberg GB, et al. Surgical versus medical castration for metastatic prostate cancer: use and overall survival in a national cohort. J Urol 2020; 203(5): 933–9. doi: 10.1097/ju.0000000000000684 DOI: https://doi.org/10.1097/JU.0000000000000684

Fleure L, Sara S. An exploration of the role of the prostate cancer specialist nurse from two international perspectives. Semin Oncol Nurs 2020; 36(4): 151043. doi: 10.1016/j.soncn.2020.151043 DOI: https://doi.org/10.1016/j.soncn.2020.151043

Saliev T, Akhmad N, Altynbekova S, Nogaeva M, Tazhieva A, Dushimova Z, et al. Role of ethnic and genetic factors in the development of prostate cancer (review). World Acad Sci J 2024; 7(1): 13. doi: 10.3892/wasj.2024.301 DOI: https://doi.org/10.3892/wasj.2024.301

Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, et al. Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics. Cancer Lett 2022; 531: 71–82. doi: 10.1016/j.canlet.2022.01.028 DOI: https://doi.org/10.1016/j.canlet.2022.01.028

Pichardo CM, Ezeani A, Acevedo AM, Agurs-Collins T, Bailey-Whyte M, Dorsey TH, et al. West African genetic ancestry, neighborhood deprivation, and prostate cancer. JAMA Netw Open 2024; 7(9): e2433546. doi: 10.1001/jamanetworkopen.2024.33546 DOI: https://doi.org/10.1001/jamanetworkopen.2024.33546

Barrington WE, Schenk JM, Etzioni R, Arnold KB, Neuhouser ML, Thompson IM Jr, et al. Difference in association of obesity with prostate cancer risk between us African American and non-Hispanic white men in the selenium and vitamin E cancer prevention trial (select). JAMA Oncol 2015; 1(3): 342. doi: 10.1001/jamaoncol.2015.0513 DOI: https://doi.org/10.1001/jamaoncol.2015.0513

Hurwitz LM, Yeboah ED, Biritwum RB, Tettey Y, Adjei AA, Mensah JE, et al. Overall and abdominal obesity and prostate cancer risk in a West African population: an analysis of the Ghana prostate study. Int J Cancer 2020; 147(10): 2669–76. doi: 10.1002/ijc.33026 DOI: https://doi.org/10.1002/ijc.33026